A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Inclusion Criteria: * Male or female subjects age 18 to 45 * A body mass index (BMI) between 18.5 and 30 kg/m2. * Good physical and mental health. * Vital signs .within the acceptable range. * Electrocardiogram (12-lead) after at least 5 minutes in supine position considered as normal or with findings considered as not clinically significant by the investigator. . * Non-smoker for at least 6 months before screening. * Subject has screening laboratory parameters within the normal ranges unless considered to be not clinically relevant by the principal investigator. . * Subject is able to review and understand an informed consent, and must sign the independent ethics committee (IEC)/IRB approved informed consent form before any trial-related procedures are performed. * Sexually active females of childbearing potential must have a negative serum pregnancy test result at screening. These subjects must use a medically acceptable method of contraception while receiving protocol-assigned product, and are expected to continue to use this method of contraception for up to 90 days following the last dose of the study medication. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Women who are not currently sexually active or lactating must agree to use 2 forms of nonhormonal contraception, should they become sexually active while participating in the study, and for 90 days following the end of participation in the study. Male subjects and/or their partners must use a medically acceptable form of contraception while receiving protocol-assigned product, and up to 90 days following the last dose of the study medication. * Subject is willing and able to take the assigned clinical trial medication as directed, comply with clinical trial instructions, and commit to all study visits. Exclusion Criteria: * History of intolerance to any of the ingredients in the study medications, or other related drugs, or history of relevant/clinically significant allergic reactions of any origin. * Any disease or physical condition that, in the opinion of the investigator, could impact the PK/pharmacodynamics of the drug or could potentially compromise the safety of the subject. * Subject has previously participated in a clinical study of albaconazole. * History of drug, prescription medicine, or alcohol abuse within the past 2 years. * Positive drug screen. * History of psychological or other emotional problems that are likely to invalidate informed consent, or could limit the ability of the subject to comply with the protocol requirements. * Any drug treatment taken within 14 days before the first drug intake or within 5 half-lives whichever is longer. * Participation in another clinical trial, blood donation, or significant blood loss less than 30 days before the first intake of study drug. * Unsuitable veins for repeated venipuncture. * Subject has any known liver disease or liver toxicity with other drugs. * Subject has a predose ECG before dosing with a QTcB or QTcF interval \>450 msec, or abnormal morphology of the ECG, or clinically serious arrhythmia. * Subjects who are pregnant, breast-feeding, women of childbearing potential not using adequate contraceptives or planning to conceive, or male subjects who plan to father a child as described in the informed consent. * Positive for hepatitis B (HBsAg) or hepatitis C (Ab HCV) or HIV or AIDS. * Consumption of any excluded drugs or foodstuff within 72 hours before dosing. * Subjects who are employees of a clinical research organization involved in the study, or Stiefel, or an immediate family member. * Subjects who have a member of the same household in this study.